Where does Progastrine et Cancers S.À R.L. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Progastrine et Cancers S.À R.L. ranks #42,457 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Progastrine et Cancers S.À R.L. hold?

Progastrine et Cancers S.À R.L. holds 6 US utility patents granted between 2021 and 2024, spanning 4 technology areas.

What is Progastrine et Cancers S.À R.L.'s Innovation Score?

Progastrine et Cancers S.À R.L. has an Innovation Score of 42.1 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Progastrine et Cancers S.À R.L. focus on?

Progastrine et Cancers S.À R.L.'s top technology area is C07K (Peptides) with 6 patents. Grants appear in 4 CPC subclasses total.

Is Progastrine et Cancers S.À R.L.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Progastrine et Cancers S.À R.L..

What does claim depth mean for Progastrine et Cancers S.À R.L.'s patents?

Progastrine et Cancers S.À R.L.'s patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Progastrine et Cancers S.À R.L. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Progastrine et Cancers S.À R.L.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Progastrine ranks #42,457 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#42,457
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.1/100): 13.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R42457 · Foreign Corporation #42,457 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #42,457/49,997
PHOTO-FINISH ProcessChamp
CPC-NARROW C07K · 4 areas
INNOV-PAR 42.1/100
CLAIMS-RICH 13.8 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2024 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: ProcessChamp, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Progastrine et… · this assignee

42
3D Lighting… · lowest

7

What this shows Progastrine's Innovation Score is 42.1/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Progastrine's grants concentrate

Progastrine et Cancers S.À R.L. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2021. By volume, Progastrine sits between ProcessChamp, LLC and Propack Processing and Packaging Systems, Inc..

Progastrine's three-year grant acceleration

Progastrine et Cancers S.À R.L. shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Processchamp

6
Procon Analytics

6
Production Plus

6
Profense

6
Progressive Neuro

6
Prokarium

6
Promontory Mortga…

6
Propack Processin…

6
Progastrine et Ca… ◀

6

What this shows Progastrine holds 6 patents at rank #42,457, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Progastrine

By rank, the assignees closest to #42,457 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Progastrine's primary technology class.

Progastrine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Progastrine et Cancers S.À R.L. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	16.7%
2023	4	66.7%
2024	1	16.7%

Which technologies does Progastrine et Cancers S.À R.L. patent most?

C07K - Peptides 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#42,457

of 49,997 tracked assignees

Innovation Score

42.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Progastrine et Cancers S.À R.L.'s patent record in context - here's where to go next.

Progastrine et Cancers S.À R.L.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #42,457 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Progastrine et Cancers S.À R.L. against ProcessChamp, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.